Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with carboplatin and nab-paclitaxel as neoadjuvant therapy for potentially resectable stage II-IIIA esophageal squamous cell carcinoma
ChiCTR2000028900Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, carboplatin and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Incidence of treatment-emergent adverse events and Safety of surgery. Started Jan 2020; status: recruiting.
02
Drugs
camrelizumabcarboplatinpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000028900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028900.